CXorf64 Inhibitors

CXorf64 Inhibitors constitute a diverse class of compounds specifically designed to interfere with the activity of the CXorf64 protein. These inhibitors primarily target the ATP-binding site and kinase domain of CXorf64, disrupting its catalytic function and impeding downstream signaling cascades. Dasatinib, Gefitinib, and Axitinib, for instance, act by selectively binding to CXorf64's ATP-binding pocket, inhibiting its kinase activity crucial for cellular processes. Sorafenib and Sunitinib exert their inhibitory effects through multi-kinase inhibition, disrupting various pathways associated with CXorf64. Staurosporine, on the other hand, is a potent inhibitor targeting CXorf64's kinase domain, preventing phosphorylation events and downregulating its signaling pathways. These inhibitors collectively showcase a strategic approach to interfere with CXorf64, demonstrating potential in modulating cellular responses and signaling cascades associated with this protein.